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concentrations. There was a dose × route interaction (P < 0.05) and route effect (P < 0.01) for increases in 
plasma carnitine above baseline, with increases above baseline being greater across all dose levels when 
infused abomasally compared to ruminally. Results demonstrated superior bioavailability of carnitine 
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Summary
This study evaluated the relative bioavailability of carnitine delivered by different meth-
ods in dairy cattle. Four Holstein heifers were used in a split-plot design to compare 
ruminally or abomasally infused L-carnitine. The study included 2 main-plot periods, 
with infusion routes allocated in a crossover design. Within main-plot periods, each of 
3 subplot periods consisted of 4-d infusions separated with 4-d rest periods. Subplot 
treatments were infusion of 1, 3, and 6 g L-carnitine daily. Doses were increased within 
a period to minimize carryover. Treatments were delivered in two 10-h infusions daily. 
Blood was collected before the start of infusions and on day 4 of each infusion to obtain 
baseline and treatment carnitine concentrations. There was a dose × route interaction 
(P < 0.05) and route effect (P < 0.01) for increases in plasma carnitine above baseline, 
with increases above baseline being greater across all dose levels when infused aboma-
sally compared to ruminally. Results demonstrated superior bioavailability of carnitine 
when ruminal exposure was physically bypassed.
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Introduction 
Fatty liver is a metabolic disease that commonly affects postpartum dairy cows. In 
response to negative energy balance that typically occurs in early lactation when feed in-
take is insufficient to meet the high energy demand of lactation, fatty acids are released 
from adipose tissue stores as an energy source. However, this lipid mobilization can de-
liver fatty acids to the liver at a rate that exceeds the organ’s oxidative capacity, resulting 
in accumulation of liver lipids which is associated with decreased metabolic function. 
L-carnitine plays an essential role in the transport of long chain fatty acids from the 
cytosol into the mitochondria of hepatocytes. Increased transport of these fatty acids 
can potentially stimulate hepatic long chain fatty acid oxidation, thereby limiting lipid 
accumulation. 
It has been clearly demonstrated that carnitine can be degraded by ruminal microbes, 
but the extent of ruminal degradation is unknown. Abomasal and ruminal infusions of 
carnitine have previously been equally effective at increasing plasma carnitine concen-
trations, suggesting some carnitine might escape ruminal degradation and be available 
1 Lonza, Inc., Allendale, NJ.
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for intestinal absorption. It has been suggested that degradation rate may be dependent 
on diet composition and the length of time animals are fed supplemental carnitine, as 
ruminal microbes seem to adapt to carnitine supplementation by increasing degrada-
tion rate. Previous studies have assumed up to 80% of supplemental carnitine is rumi-
nally degraded in lactating dairy cows. The objective of this study was to evaluate the 
relative bioavailability of carnitine when administered at different sites in the rumen 
gastrointestinal tract at varying rates.
Experimental Procedures 
Four Holstein heifers previously fitted with ruminal cannulas were used in a split-plot 
design to assess the relative bioavailability of ruminally or abomasally administered L-
carnitine. However, one heifer was removed just prior to the end of the first treatment 
period due to an intestinal blockage requiring surgery. A second heifer was removed due 
to an infection during phase 2 of period 2, and the first heifer removed from the study 
replaced her at that time. The study was therefore an incomplete design. Heifers were 
housed in a tie-stall facility and fed a dairy ration once daily. The diet met estimated 
requirements for all nutrients and was supplemented with niacin (7.8 g/day niacin in 
the form of 12 g/day Niashure, Balchem Corp., New Hampton, NY). 
The study was conducted in 2 periods, both preceded by 2 weeks without treatment to 
obtain baseline samples and for washout between periods. Each period had 3 phases, 
each consisting of 4 days of infusions at a different dose of carnitine, with 4 days be-
tween phases. The treatments were 1) ruminal infusion of carnitine at 1, 3, and 6 g 
carnitine/day and 2) abomasal infusion of 1, 3, and 6 g carnitine/day. Each carnitine 
treatment was dissolved in water and also included 6 g/day of larch arabinogalactan, 
and total volume infused was 4 L/day across treatments. The dosage used in each phase 
escalated, with phase 1 at 1 g/day, phase 2 at 3 g/day, and phase 3 at 6 g/day. The site 
of infusion was randomized; 2 heifers received ruminal infusions in period 1, followed 
by abomasal infusions in period 2, and the other heifer was treated in the opposite 
sequence. Daily infusions (throughout each 4-day infusion) were split into 2 equal 
aliquots, each infused during 10-hour infusion periods, allowing 2 hours between infu-
sions. 
Throughout the study, feed and water intake were recorded daily with the final three 
days of each infusion phase used for analysis. Total mixed ration samples were collected 
every two weeks and composited for nutrient analysis by Dairy One Forage Laboratory 
(Ithaca, NY; Table 1). Health was monitored daily. 
Prior to the start of infusions and at 1.5 hours after initiation of the first daily infusion 
on day 4 of each phase, blood samples (coccygeal vein) were collected to obtain baseline 
and treatment carnitine concentrations. Concentrations of total carnitine in plasma 
were determined by an enzymatic radioisotope method. 
Statistical analysis was performed using JMP (version 12, SAS Institute, Cary, NC). 
Dependent variables (feed intake, water intake, and change in plasma carnitine concen-
tration) were analyzed to determine the fixed effects of route of administration, dose 
of carnitine, and their interaction along with the random effects of heifer and phase 
within period. Contrast statements were used to statistically test linear regression coef-
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ficients with increasing doses for ruminal vs. abomasal infusions, and least square means 
were regressed against dose for the 2 infusion routes to assess relative bioavailability. 
Significance was declared at P < 0.05 and tendencies were declared at 0.05 ≤ P ≤ 0.10.
Results and Discussion 
Water intake was not affected by carnitine infusion across dose or route (all P > 0.40; 
Table 2). Although not affected by infusion route (P = 0.13), dry matter intake (DMI) 
did tend to increase quadratically with carnitine dose (P = 0.07), being highest for 
the 3 g/day carnitine. The tendency for a DMI effect is likely the result of our small 
sample size and was largely driven by data from one heifer. Previous studies have not 
documented DMI responses when carnitine was infused abomasally or ruminally up 
to 12 g/d. When carnitine was abomasally infused at a high rate (100 g/d), DMI was 
decreased during the first two weeks of lactation. 
Plasma carnitine concentrations are reported as the difference between baseline and 
treatment concentrations in Table 2. A dose × route interaction was observed (P = 
0.045), which can largely be attributed to the linear increase in plasma carnitine con-
centrations with increased dose for abomasal infusion, without a significant effect for 
ruminal infusions. A route response was observed (P = 0.005) with carnitine being 
more bioavailable across all dose levels when infused abomasally compared to ruminally. 
Interestingly, increases in plasma carnitine concentrations in response to ruminal infu-
sion appeared to plateau at 3 g/d; this could be impacted by the sequence of treatments, 
given that adaptation of ruminal microbes may enhance carnitine degradation after 
a longer period of exposure. It is also possible that L-carnitine transport from the gut 
reaches an upper limit at these doses. To further characterize the relative bioavailabil-
ity of carnitine via these 2 routes of administration, a dose-response analysis was con-
ducted (Figure 1). This assessment suggests that the relative bioavailability of carnitine 
is greater when supplied to the abomasum vs. the rumen. It should be noted that this 
assumes that increases in plasma concentration are directly related to the amount of 
carnitine absorbed.
Conclusion 
Carnitine is likely degraded in the rumen, and although the extent of degradation 
remains unknown, our findings clearly indicate abomasal administration of carnitine 
results in superior bioavailability. Dietary supplementation with rumen encapsulation 
may be most effective to maximize carnitine delivery and absorption in the small intes-
tine. 
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Table 1. Ingredient and nutritional composition of the basal diet 
Item Value
Ingredient, % of dry matter
 Alfalfa hay 21.0
 Grass hay 1.7
 Corn silage 16.1
 Wet corn gluten feed1 25.7
 Cotton seed 4.4
 Fine rolled corn 20.4
 Micronutrient premix2 10.7
Nutrient, % of dry matter (unless otherwise specified)
 Dry matter, % as-fed 53.5
 Crude protein 17.9
 Acid detergent fiber 24.75
 Neutral detergent fiber 43.8
 Lignin 4.55
 Non-fiber carbohydrate 26.75
 Starch 17.9
 Crude fat 4.75
 Net energy for lactation,3 Mcal/lb 0.73
1Sweet Bran (Cargill Inc., Blair, NE).
2Premix consisted of 58.8% expeller soybean meal (SoyBest, Grain States Soya, West Point, NE), 11.8% limestone, 
1.47% stock salt, 1.47% trace mineral salt, 1.47% potassium chloride, 10.3% sodium bicarbonate, 2.35% magne-
sium oxide. 0.23% 4-Plex (Zinpro Corp., Eden Prairie, MN), 0.12% Zinpro 100 (Zinpro Corp.), 0.25% selenium 
premix (0.06%), 0.15% vitamin A premix (30 kIU/g), 0.04% vitamin D premix (30 kIU/g), 1.47% vitamin E 
premix (48 kIU/g), 0.01% ethylenediamine dihydriodide premix, 0.06% Rumensin 90 (Elanco Animal Health, 
Greenfield, IN), 1.84% XP Yeast (Diamond V, Cedar Rapids, IA), 0.92% Biotin 100 (ADM Alliance Nutrition, 
Quincy, IL), and 7.35% Ca salts of long-chain fatty acids (Megalac R, Arm & Hammer Animal Nutrition, Princ-
eton, NJ). 
Table 2: Effect of carnitine infusion on intake performance and plasma carnitine concentration
Ruminal infusion (/day) Abomasal infusion (/day) P - value
Item 1 g 3 g 6 g 1 g 3 g 6 g pSEM1 Dose Route
Dose × 
route
DMI, kg/d 18.01 18.76 18.87 16.84 19.01 17.43 0.97 0.07 0.13 0.35
Water intake, L/d 7.71 8.04 8.60 8.27 9.24 7.88 0.69 0.66 0.58 0.41
Plasma,2 µM -0.57 12.33 9.04 4.54 20.47 35.90 4.82 0.099 < 0.01 0.045
1Reported SEM is pooled across route and dose levels. 
2Plasma concentrations reported are the difference between baseline and treatment concentrations. 


































y = 6.1829x - 0.3063
R2 = 0.98466
y = 1.6837x - 1.3211
R2 = 0.39958
Figure 1. Marginal plasma carnitine responses to carnitine infusion differ by infusion 
route. Differences in plasma carnitine concentrations (post minus pre-infusion concen-
trations) are plotted against infusion amount. The slopes differ between infusion routes 
(P = 0.02), reflecting greater apparent bioavailability for abomasally-delivered carnitine 
compared to ruminal infusion.
